Related Experiment Video

Updated: Jun 19, 2026

Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting
07:54

Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting

Published on: March 25, 2019

Nanomolecular targeting of dendritic cells for ovarian cancer therapy

Juan R Cubillos-Ruiz, Steven Fiering, Jose R Conejo-Garcia

    Future Oncology (London, England)
    |October 27, 2009
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
    09:48

    Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

    Published on: August 23, 2024

    Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo
    10:35

    Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo

    Published on: February 5, 2021

    Related Experiment Videos

    Last Updated: Jun 19, 2026

    Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting
    07:54

    Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting

    Published on: March 25, 2019

    Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
    09:48

    Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

    Published on: August 23, 2024

    Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo
    10:35

    Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo

    Published on: February 5, 2021

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...

    Articles linked to this work by shared authors, journal, and citation graph.

    BCL11B targeting in tumor CD8 + T cells amplifies anti-tumor response by blocking exhaustion while promoting stemness and cytotoxicity.

    bioRxiv : the preprint server for biology·2026

    Tumor-infiltrating plasma cell profiling after PD-1 blockade reveals tumor-specific antibodies.

    Cancer cell·2026

    Isotype-switched antibodies originating from tertiary lymphoid structures can antagonize ovarian cancer progression.

    iScience·2026

    Ovarian cancer tumor immune profiles associated with intrauterine device and oral contraceptive use.

    British journal of cancer·2026

    Characterization of Anti-Canine PD-1 Antibodies.

    Cells·2026

    Spatially Defined Cellular Niches Forged by Tumor-Intrinsic MHCII Redefine Immune Competence in Ovarian Cancer.

    Cancer discovery·2026

    First-line management of unresectable hepatocellular carcinoma: clinical perspectives from the CheckMate 9DW study.

    Future oncology (London, England)·2026

    A patient's experience with follicular lymphoma from diagnosis to cure: the life-changing impact of CAR T-cell therapy.

    Future oncology (London, England)·2026

    The role of contrast enhanced ct plus pan-immune-inflammation value in predicting outcomes of hepatocellular carcinoma after hepatectomy.

    Future oncology (London, England)·2026

    Translating avelumab maintenance into clinical practice: nationwide outcomes in Czech patients with advanced or metastatic urothelial carcinoma.

    Future oncology (London, England)·2026

    Efficacy of anlotinib plus immune checkpoint inhibitors in soft-tissue sarcoma: systematic review and meta-analysis.

    Future oncology (London, England)·2026

    MH-Penile-002: a phase II, prospective, single-arm trial of neoadjuvant anti-EGFR antibody-drug conjugate plus PD-1 inhibitor in penile cancer with challenging penile preservation or regional lymph node metastasis.

    Future oncology (London, England)·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us